Professional
Added to YB: 2025-01-13
Pitch date: 2025-01-10
TMDX [bearish]
TransMedics Group, Inc.
-94.73%
current return
Author Info
Scorpion Capital specializes in intensive, differentiated research which uncovers what investors have missed and Wall Street is paid to ignore. Sign up for the newsletter.
Company Info
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Market Cap
$4.5B
Pitch Price
$65.11
Price Target
N/A
Dividend
N/A
EV/EBITDA
35.52
P/E
51.63
EV/Sales
7.99
Sector
Health Care Equipment and Supplies
Category
special_situation
Scorpion Capital: We are short TransMedics ($TMDX)
TMDX short: Device failures plague OCS pumps, causing organ loss & necrosis. Centers report 5-20% failure rate. Surgeons allege cover-up, refusal to publish safety data. Ex-employees claim CEO pressured to doctor reports, not report to FDA. MGH exec: 'bombardment of issues', 'running joke' in field. Calls for recall ignored. NRP rapidly displacing at $3K vs $100K+.
Read full article (84 min)